ArticleJournal of immunology research2015
The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren's Syndrome.
Article in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Associations Between Th17 Cell Markers (IL-23R, CCR6, and IL-17) and Clinical Profiles in Sjögren's Disease.Diagnostics (Basel, Switzerland) · 2025Article
- Immunobiology roles of the human CD161 receptor in T cells.Frontiers in immunology · 2025Review
- Study of pathogenic T-helper cell subsets in Asian Indian patients with Takayasu arteritis.Immunologic research · 2024Article
- The proportion of CD161 on CD56Immunity, inflammation and disease · 2024Article
- Article
- MICa/b-dependent activation of natural killer cells by CD64The EMBO journal · 2023Article
- Allergic disorders and their risk factors in primary Sjögren's syndrome.The World Allergy Organization journal · 2023Article
- Contributions of Major Cell Populations to Sjögren's Syndrome.Journal of clinical medicine · 2020Review
- Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sjögren's Syndrome.Current rheumatology reviews · 2018Review
- MicroRNA in Sjögren's Syndrome: Their Potential Roles in Pathogenesis and Diagnosis.Journal of immunology research · 2018Review
- CD147-mediated chemotaxis of CD4Clinical rheumatology · 2018Article
- Clinical Efficacy and Safety of Total Glucosides of Paeony for Primary Sjögren's Syndrome: A Systematic Review.Evidence-based complementary and alternative medicine : eCAM · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTh17 cells have been demonstrated to play an important role in the onset and development of primary Sjögren's syndrome (pSS). In this study, we evaluated the expansion and clinical significance of circulating CD4+CD161+ T cell and its "effector" (CD4+CD25-CD161+ T cell) and "regulatory" (CD4+CD25+CD161+ T cell) subpopulations.
methodsFifty-eight pSS patients and 16 healthy controls (HCs) were recruited in our study. The cell populations and intracellular IL-17 expression were analyzed by flow cytometry. The disease activity was evaluated by the EULAR-SS Disease Activity Index (ESSDAI). Autoantibodies were measured by ELISA or indirect immunofluorescence assay.
resultsThe CD161+ T cell fractions showed higher proportions of IL-17-producing cells. The frequencies of the overall CD4+CD161+ T cell population and its effector subset were positively correlated with disease activity parameters and more severe disease manifestations. A significant elevation of the CD4+CD25+CD161+ T cell subpopulation was observed in the peripheral blood of pSS patients compared to HCs and this subset showed decreased regulatory functions compared with the CD4+CD25+CD161- population.
conclusionCirculating CD4+CD161+ T cell populations associated with pSS disease activity and severity. These cells might be involved in the development of pSS and could be potential therapeutic targets in the treatment of pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.